Cancer Immunotherapy and Biomarkers

The paper develops a method combining multiplexed imaging and proteomics to analyze tumor microenvironments, identifying immune cell interactions and adaptations in colorectal and tonsil cancers.

This study compares immunotherapy responses in subcutaneous and orthotopic dMMR LUAD models, finding that orthotopic models show better anti-PD1 response with increased immune infiltration and CD4+ memory T cells.

This study develops a 37-marker spectral flow cytometry assay for high-dimensional immunophenotyping of cryopreserved liquid biopsies and validates its robustness against cryopreservation effects.

The paper assesses T-cell dynamics in pediatric cancer patients during treatment, finding that immune checkpoint proteins and T-cell subsets change with therapy, and introduces a Dynamic Immunogenomic Score to predict relapse risk.

This study examines the spatial organization of dendritic cell (DC) subsets and their interactions with CD8+ T cells in melanoma patients, finding that proximity between cDC1 and CD8+ T cells correlates with response to immune checkpoint inhibitors.

This study identifies a four amino acid motif in VISTA that suppresses tumor growth by altering EGFR signaling through NUMB recruitment.

This study compares human and rodent PD1 proteins, finding rodent PD1 has weaker inhibitory activity and stronger tumor immunity due to evolutionary changes in Shp2 recruitment.

The paper shows that IFN-gamma-insensitive tumours can still be controlled by immune responses, with IFN-gamma driving myeloid cell remodelling that enhances anti-tumour immunity.

This study identifies SOX2 expression in lung cancer cells as a mechanism causing resistance to checkpoint blockade by promoting Treg-dependent CD8+ T cell exclusion.

This study evaluates TMB cutoffs for predicting immunotherapy outcomes across multiple cancer types and endpoints, finding replicable associations for specific cutoffs in melanoma, lung, and bladder cancers.

This study shows that combining immunotherapies can lead to divergent tumor responses based on the tumor microenvironment, with Treg depletion reversing progression in pancreatic cancer.

This paper shows that combining PARP14 inhibition with PD-1 blockade enhances immune responses in melanoma by promoting T cell quiescence and modulating macrophage polarization.

This study identifies immune suppressive barriers in preinvasive lung cancer progression using single-cell analyses, revealing key cellular and spatial changes that could inform therapeutic strategies.

This paper shows that immune checkpoint blockade (ICB) can delay cancer onset and improve survival in mice with mutator syndromes, but only if administered prophylactically before tumors develop.

The paper generates and characterizes primary human cytotoxic T cells with suppressed function in vitro, showing their resemblance to exhausted tumor-infiltrating CTL and identifying factors affecting their effector function.

The paper identifies tumor-associated macrophages as key drivers of T cell exhaustion transition, showing their role in shifting progenitor exhausted T cells to terminal exhaustion and impacting immunotherapy response.

This study shows that PD-1 knockout mice with genome mutations develop liver granulomatous inflammation, supporting PD-1's role in suppressing autoimmune responses to neoantigens.

The paper shows antimitotic chemotherapy induces a NF-kB secretory phenotype in triple-negative breast cancer, promoting immunosuppressive CXCR2+ neutrophil chemotaxis, and demonstrates that CXCR2 inhibition enhances antitumor immunity.

The paper identifies PD-1 deficiency in mice leads to increased CD8+ T cells in the submandibular gland, resembling immune-related adverse events, and shows NK cells regulate these cells via the PD-1/PD-L1 axis.

This study shows that CRACD inactivation in gastric cancer leads to immune evasion via oxidative stress-activated PD-L1, suggesting HIF1 and PD-L1 as therapeutic targets.

This paper develops and tests Anti-4CB1, an anti-HVEM monoclonal antibody, showing enhanced anti-tumor activity in vitro and in vivo, particularly when combined with Anti-PD1, and correlates HVEM expression with treatment response.

The paper identifies unique neoantigen profiles in Kenyan breast cancer patients using whole exome and RNA sequencing data, highlighting patient-specific mutations and HLA associations.

This paper reviews biomarkers for immune checkpoint blockade therapy, compares existing databases, and introduces IOhub, a web portal for benchmarking biomarkers using bulk and single-cell transcriptome datasets.

The paper uses spatial transcriptomics to identify increased spatial coupling of integrin and collagen IV in immunoresistant clear cell renal cell carcinoma tumors, suggesting integrin as a therapeutic target.

This study investigates the combination of TLR8 agonism and PD-1 blockade in HNSCC patients, finding increased innate immune activation and dendritic cell-T cell interactions.

The paper identifies two TRM subpopulations in NSCLC patients and shows that only DP TRM predicts response to PD-1 blockade immunotherapy.

This study shows chemotherapy causes myeloid-driven spatial T-cell exhaustion in ovarian cancer by altering immune cell states and interactions, suggesting new immunotherapy approaches.

The paper develops a spatially resolved model to show how immune cell organization and dynamics influence response to immune checkpoint inhibitors in melanoma patients.

The paper uses spatial proteomics and transcriptomics to analyze sentinel lymph nodes in melanoma patients, identifying immune patterns that predict distant metastases.

The paper identifies Mif as a regulator of tumor immune evasion in low intra-tumor heterogeneity melanoma by analyzing single-cell RNA sequencing data and validating in patient data.